
Zhejiang Shengda Bio-Pharm Co., Ltd.
SSE:603079.SS
16.62 (CNY) • At close June 11, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 827.402 | 727.406 | 738.019 | 789.733 | 867.315 | 519.15 | 492.71 | 508.561 | 482.148 | 536.429 | 380.897 | 398.771 | 449.254 |
Cost of Revenue
| 651.452 | 653.221 | 607.173 | 561.272 | 393.735 | 326.62 | 327.405 | 316.247 | 310.542 | 262.502 | 244.058 | 263.06 | 221.261 |
Gross Profit
| 175.95 | 74.184 | 130.846 | 228.461 | 473.579 | 192.53 | 165.305 | 192.314 | 171.606 | 273.928 | 136.839 | 135.711 | 227.993 |
Gross Profit Ratio
| 0.213 | 0.102 | 0.177 | 0.289 | 0.546 | 0.371 | 0.336 | 0.378 | 0.356 | 0.511 | 0.359 | 0.34 | 0.507 |
Reseach & Development Expenses
| 43.762 | 42.925 | 37.418 | 39.643 | 35.686 | 27.901 | 21.386 | 22.878 | 23.905 | 26.624 | 21.039 | 18.028 | 23.146 |
General & Administrative Expenses
| 17.908 | 15.15 | 14.032 | 34.895 | 53.68 | 25.643 | 20.003 | 18.386 | 24.46 | 61.035 | 11.554 | 62.658 | 111.761 |
Selling & Marketing Expenses
| 6.768 | 5.889 | 13.249 | 12.472 | 28.582 | 18.496 | 17.121 | 15.329 | 19.752 | 21.365 | 14.92 | 13.381 | 24.911 |
SG&A
| 24.676 | 77.26 | 27.282 | 47.367 | 82.262 | 44.139 | 37.124 | 33.714 | 44.212 | 82.4 | 26.475 | 76.039 | 136.672 |
Other Expenses
| 60.945 | -0.325 | 43.945 | 65.249 | 74.271 | 49.538 | 1.077 | -0.831 | 10.63 | -0.423 | 0.266 | 21.486 | -4.394 |
Operating Expenses
| 129.384 | 119.206 | 108.645 | 152.259 | 192.219 | 121.578 | 106.913 | 88.751 | 114.947 | 153.745 | 78.998 | 79.438 | 140.228 |
Operating Income
| 46.566 | -45.676 | 59.411 | 81.444 | 247.306 | 76.711 | 52.299 | 85.82 | 63.453 | 109.839 | 50.579 | 46.709 | 74.842 |
Operating Income Ratio
| 0.056 | -0.063 | 0.081 | 0.103 | 0.285 | 0.148 | 0.106 | 0.169 | 0.132 | 0.205 | 0.133 | 0.117 | 0.167 |
Total Other Income Expenses Net
| 2.519 | 0.368 | -22.887 | -1.403 | -23.632 | -1.506 | 0.1 | 0.146 | 9.903 | -1.722 | -0.53 | 20.336 | -5.198 |
Income Before Tax
| 49.085 | -45.308 | 36.524 | 80.042 | 223.674 | 49.175 | 52.399 | 85.966 | 72.985 | 108.116 | 50.05 | 67.045 | 69.644 |
Income Before Tax Ratio
| 0.059 | -0.062 | 0.049 | 0.101 | 0.258 | 0.095 | 0.106 | 0.169 | 0.151 | 0.202 | 0.131 | 0.168 | 0.155 |
Income Tax Expense
| 11.828 | 8.894 | 6.084 | 8.219 | 33.702 | 11.416 | 9.815 | 13.356 | 12.05 | 21.413 | 6.264 | 9.953 | 16.234 |
Net Income
| 29.424 | -54.063 | 31.484 | 75.756 | 197.438 | 47.03 | 44.544 | 72.61 | 60.936 | 86.703 | 43.785 | 54.592 | 52.36 |
Net Income Ratio
| 0.036 | -0.074 | 0.043 | 0.096 | 0.228 | 0.091 | 0.09 | 0.143 | 0.126 | 0.162 | 0.115 | 0.137 | 0.117 |
EPS
| 0.17 | -0.32 | 0.18 | 0.44 | 1.17 | 0.3 | 0.29 | 0.56 | 0.52 | 0.74 | 0.37 | 0.49 | 0.47 |
EPS Diluted
| 0.17 | -0.32 | 0.18 | 0.44 | 1.17 | 0.3 | 0.29 | 0.56 | 0.52 | 0.74 | 0.37 | 0.49 | 0.47 |
EBITDA
| 126.084 | 34.449 | 114.417 | 163.803 | 302.855 | 111.559 | 92.102 | 119.371 | 91.441 | 140.777 | 80.909 | 56.273 | 87.766 |
EBITDA Ratio
| 0.152 | 0.047 | 0.155 | 0.207 | 0.349 | 0.215 | 0.187 | 0.235 | 0.19 | 0.262 | 0.212 | 0.141 | 0.195 |